Melanoma future or investigational therapies

Melanoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Melanoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Genetic Counselling

Cost-Effectiveness of Therapy

Future or Investigational Therapies

2019 AAD Guidelines for management of Primary Cutaneous Melanoma (CM)

Guidelines for Diagnosis of Primary CM

Guidelines for Treatment of Primary CM

Guidelines for management of Primary CM in Pregnancy

Case Studies

Case #1

Melanoma future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Melanoma future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Melanoma future or investigational therapies

CDC on Melanoma future or investigational therapies

Melanoma future or investigational therapies in the news

Blogs on Melanoma future or investigational therapies

Directions to Hospitals Treating Melanoma

Risk calculators and risk factors for Melanoma future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:  Anum Ijaz M.B.B.S., M.D.[2]

## Future Techniques[edit | edit source]

* Optical Coherence Tomography (OCT)

In addition to identifying high-risk patients, researchers also want to identify high-risk lesions within a given patient. Many new technologies, such as optical coherence tomography (OCT), are being developed to accomplish this. OCT allows pathologists to view 3-D reconstructions of the skin and offers more resolution than past techniques could provide. In vivo confocal microscopy and fluorescently tagged antibodies are also proving to be valuable diagnostic tools.

* Tumor-informed circulating DNA (ctDNA) Assay

Small cohort studies demonstrate that ctDNA positivity may predict relapse, detected either on imaging (radiographic) or by symptoms and exam (clinical). [1]. Ongoing studies are evaluating whether ctDNA can detect early relapse in resected melanoma, identifying molecular recurrence (tumor DNA in blood before clinical or radiographic evidence) to guide earlier treatment. [3]

## References[edit | edit source]

1. ↑ Eroglu Z, Krinshpun S, Kalashnikova E, Sudhaman S, Ozturk Topcu T, Nichols M, Martin J, Bui KM, Palsuledesai CC, Malhotra M, Olshan P, Markowitz J, Khushalani NI, Tarhini AA, Messina JL, Aleshin A (June 2023). "Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients". Cancer. 129 (11): 1723–1734. doi:10.1002/cncr.34716. PMID 36869646 Check `|pmid=` value (help).

Template:WikiDoc Sources